Navigation Links
BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow
Date:5/20/2011

SAN JOSE, Calif., May 20, 2011 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), launched today the BD FACSVerse™ Flow Cytometer, a flexible, reliable and scalable system that can analyze up to 10 parameters and support a wide range of research applications.  

“We engineered cutting-edge innovation into the BD FACSVerse System from the ground up, with three foundations in mind,” said James Glasscock, President of Cell Analysis, BD Biosciences.  “First, we wanted to provide researchers with a single system that could handle routine applications along with complex multi-color experiments with precision and reproducibility.  Second, we sought to streamline workflow and make the system easy to use with built-in intelligence. Lastly, we wanted to help protect our customers’ investment by giving them an upgrade path from 6 parameters up to 10 parameters as well as multiple optional capabilities that will allow them to meet the future demands of their research.”

With the new BD FACSuite™ Software System for the BD FACSVerse Flow Cytometer, users can now automate routine tasks, such as instrument startup, setup, sample acquisition, and data analysis, and complete others with minimal clicks  The software package's modular architecture enables users to multitask, performing data analysis while the system is acquiring data. According to Glasscock, the software introduces a powerful new paradigm that eliminates the need for daily spill over correction, which is essential for today's multicolor analysis.  BD FACSuite Software enables assays and experiments to be exported to other BD FACSVerse Systems around the globe, minimizing commonly encountered system and user-related variances.

The BD FACSVerse Flow Cytometer has built-in intelligence that is intended to reduce errors, increase efficiency, automate processes and minimize user interaction. Some examples include:

  • Vacuum-based fluidic subsystem that allows exceptional flexibility in sample introduction;
  • New setup and QC concepts that eliminate the need for daily compensation for standard fluorochromes; and,
  • Intelligence and innovation that are built into components across the system that streamline many operations and prevent errors

To support a wide range of applications, the system provides optional predefined BD research assays for apoptosis, cell cycle, cell proliferation, and cytokine detection, which are matched with BD reagent kits for reproducible results. The system also facilitates the development of user-defined experiments.  Researchers can convert their experiments to reusable assays that include relevant settings, acquisition and analysis worksheets, and gating strategies.  They can also establish report parameters to reduce data variability between users and laboratories for the same application.

The BD FACSVerse Flow Cytometer is available in 4-color, 6-color and 8-color configurations with forward-scatter and side-scatter support for up to 10 total parameters. The 4- and 6-color systems can be expanded with a field upgrade. The system has a compact footprint that enables it to fit easily on standard laboratory bench tops.  

For more information on the BD FACSVerse Flow Cytometer, please visit: http://bdbiosciences.com/go/verse

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact: Jeff Ezell
BD Public Relations
(201) 847-5533
Jeff_Ezell@bd.com


'/>"/>
SOURCE BD-Becton Dickinson
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Biosciences Acquires Brightwell Technologies
2. Ardea Biosciences to Present at Two Upcoming Investor Conferences
3. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
4. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
5. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
6. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
7. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
8. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
9. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
10. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
11. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
Breaking Medicine News(10 mins):